David has seen medicine’s shift in views on psychedelics. In the past, many practitioners were nervous to even consider using these substances in treatment, but now, Alberta is leading the way in exploring their potential benefits in a clinical setting. However, a lack of trained therapists and professionals to serve this industry has been a challenge. ATMA has taken a holistic and individualized approach to clinical trials, prioritizing the needs and experiences of each patient. This approach is in contrast to the one-size-fits-all approach taken by many other organizations conducting trials elsewhere in the world. ATMA is paving the way for responsible and effective use of psychedelics in mental health treatment. As the industry grows, Alberta is poised to become a leader in psychedelic-assisted therapy.